Trials / Completed
CompletedNCT00702494
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- BioInvent International AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TB-403 | Multiple IV |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-06-20
- Last updated
- 2022-03-16
Locations
2 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00702494. Inclusion in this directory is not an endorsement.